Potential therapies for anaplastic lymphoma kinase-driven tumors in children: Progress to date

Pediatric Drugs

Volumn 15, Issue 3, 2013, Pages 163-169

  Lowe, Eric J ^a   Lim, Megan S ^b  

^a CHILDREN S HOSPITAL OF THE KING S DAUGHTERS   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ACYLIMINOBENZIMIDAZOLE DERIVATIVE; AF 802; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; AP 26113; ASP 3026; BP 1 102; CH 5424802; CRIZOTINIB; CYTARABINE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; GSK 1838705; GSK 2141795; HEAT SHOCK PROTEIN 90; IMATINIB; ISOTRETINOIN; JANUS KINASE 3; LDK 378; METHOTREXATE; NMS E 628; NUCLEOPHOSMIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN; TANESPIMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; X 396;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CHILDHOOD CANCER; CHROMOSOME TRANSLOCATION; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; EDEMA; ENZYME ACTIVITY; ESOPHAGUS CANCER; FEVER; GENE AMPLIFICATION; GENE MUTATION; GLIOBLASTOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LARGE CELL LYMPHOMA; LIVER CANCER; LUNG CANCER; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LYMPHOMA; NAUSEA; NEUROBLASTOMA; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA CELL GRANULOMA; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; RHABDOMYOSARCOMA; SALVAGE THERAPY; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN CANCER; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR BLEEDING; VISUAL DISORDER; VOMITING;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; CHILD; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MUTATION; NEOPLASMS; NEOPLASMS, MUSCLE TISSUE; NEUROBLASTOMA; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC;

EID: 84878756594     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-013-0027-3     Document Type: Article

References (50)

1. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411(6835):355-65.
2. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1):11-23.
3. Webb TR, Slavish J, George RE, Look AT, Xue L, Jiang Q, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther. 2009;9(3):331-56.
4. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994;263(5151):1281-4.
5. Scheijen B, Griffin JD. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene. 2002;21(21):3314-33.
6. Grande E, Bolos MV, Arriola E. Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol Cancer Ther. 2011;10(4):569-79.
7. George RE, Sanda T, Hanna M, Frohling S, Luther W 2nd, Zhang J, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455(7215):975-8.
8. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455(7215):930-5.
9. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin's lymphoma in childhood. N Engl J Med. 1996;334(19):1238-48.
10. Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66(4):848-58.
11. Swerdlow SH, Campo E, Harris NL, Jaffé E, Pileri S, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
12. Lowe EJ, Sposto R, Perkins SL, Gross TG, Finlay J, Zwick D, et al. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941. Pediatr Blood Cancer. 2009;52(3):335-9.
13. Laver JH, Kraveka JM, Hutchison RE, Chang M, Kepner J, Schwenn M, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005;23(3):541-7.
14. Le Deley MC, Rosolen A, Williams DM, Horibe K, Wrobel G, Attarbaschi A, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol. 2010;28(25):3987-93.
15. Rosolen A, Pillon M, Garaventa A, Burnelli R, d'Amore ES, Giuliano M, et al. Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer. 2005;104(10):2133-40.
16. Seidemann K, Tiemann M, Schrappe M, Yakisan E, Simonitsch I, Janka-Schaub G, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster group trial NHL-BFM 90. Blood. 2001;97(12):3699-706.
17. Woessmann W, Peters C, Lenhard M, Burkhardt B, Sykora KW, Dilloo D, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents: a Berlin-Frankfurt-Munster group report. Br J Haematol. 2006;133(2):176-82.
18. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369(9579):2106-20.
19. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341(16):1165-73.
20. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324-34.
21. Mosse YP, Wood A, Maris JM. Inhibition of ALK signaling for cancer therapy. Clin Cancer Res. 2009;15(18):5609-14.
22. Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, Perlman EJ. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 1999;59(12):2776-80.
23. Lawrence B, Perez-Atayde A, Hibbard MK, Rubin BP, Dal Cin P, Pinkus JL, et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol. 2000;157(2):377-84.
24. Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol. 2008;61(4):428-37.
25. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-17.
26. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007;6(12 Pt 1):3314-22.
27. Christensen JG. Proof of principle for crizotinib in anaplastic lymphoma kinase-positive malignancies was achieved in ALK-positive nonclinical models. Mol Cancer Ther. 2011;10(11):2024.
28. ®. 2011. http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2011/202570s000lbl.pdf. Accessed July 2012.
29. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med. 2011;364(8):775-6.
30. Stasia A, Guerra L, Berbard L, Cohen A, King M, Ordemann R, et al. Crizotinib obtains durable responses in advanced chemoresistant ALK + lymphoma patients [abstract no. 1153]. Haematologica. 2012;97(SUPPL.):478.
31. Mosse YP, Balis FM, Lim MS, Laliberte J, Voss SD, Fox E, et al. Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: a Children's Oncology Group phase I consortium study. J Clin Oncol. 2012;30(SUPPL.; abstr 9500).
32. Zhang S, Wang F, Keats J, Ning Y, Wardwell SD. AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066). Proc Am Assoc Cancer Res. 2010;51:abstract LB-298.
33. Kiura K, Seto T, Yamamoto N, Nishio M, Nakagawa K, Tamura T. A first-in-human phase I/II study of ALK inhibitor CH5424802 in patients with ALK-positive NSCLC. J Clin Oncol. 2012;30(SUPPL.; abstr 7602).
34. Mehra R, Camidge DR, Sharma S, Felip E, Tan D, Vansteenkiste JF, et al. First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors. J Clin Oncol. 2012;30(SUPPL.; abstr 3007).
35. Kuromitsu S, Mori M, Shimada I, Kondoh Y, Shindoh N, Soga T, et al. Antitumor activities of ASP3026 against EML4-ALK-dependent tumor models. In: Proceedings of the AACR-NCI-EORTC international conference 12-16 Nov 2011. Mol Cancer Ther. 2011;10(11 SUPPL.):abstract A227.
36. Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res. 2011;71(14):4920-31.
37. Carpenter EL, Haglund EA, Mace EM, Deng D, Martinez D, Wood AC, et al. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. Oncogene. 2012;31(46):4859-67.
38. Gambacorti-Passerini C. Part I: milestones in personalised medicine - imatinib. Lancet Oncol. 2008;9(6):600.
39. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009;27(31):5175-81.
40. Ait-Tahar K, Damm-Welk C, Burkhardt B, Zimmermann M, Klapper W, Reiter A, et al. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood. 2010;115(16):3314-9.
41. Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011;19(5):679-90.
42. Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA. 2011;108(18):7535-40.
43. Lewis RT, Bode CM, Choquette DM, Potashman M, Romero K, Stellwagen JC, et al. The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer. J Med Chem. 2012;55(14):6523-40.
44. Goulden S, Sutcliffe F, Stevens A. NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib. Lancet Oncol. 2012;13(2):127-8.
45. Cussac D, Greenland C, Roche S, Bai RY, Duyster J, Morris SW, et al. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp 60c-src to mediate its mitogenicity. Blood. 2004;103(4):1464-71.
46. Schumacher JA, Crockett DK, Elenitoba-Johnson KS, Lim MS. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells. Proteomics. 2007;7(15):2603-16.
47. Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. 2001;61(5):2194-9.
48. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med. 2005;11(6):623-9.
49. Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci USA. 2012;109(24):9623-8.
50. Chiarle R, Martinengo C, Mastini C, Ambrogio C, D'Escamard V, Forni G, et al. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med. 2008;14(6):676-80.